Quantum Biopharma (QNTM) Expected to Announce Quarterly Earnings on Friday

Quantum Biopharma (NASDAQ:QNTM) is expected to be releasing its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Quantum Biopharma Trading Down 8.0%

QNTM opened at $4.35 on Thursday. Quantum Biopharma has a 12 month low of $2.07 and a 12 month high of $38.25. The business’s 50-day moving average price is $4.07 and its 200-day moving average price is $8.94. The company has a market cap of $16.60 million, a P/E ratio of -0.40 and a beta of 0.32.

Institutional Investors Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Jane Street Group LLC purchased a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned approximately 0.29% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on QNTM. Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. Wall Street Zen lowered Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Quantum Biopharma has a consensus rating of “Sell”.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.